Tip:
Highlight text to annotate it
X
Rick Baehner: Ductal carcinoma in situ or DCIS is a precancerous condition in which
the abnormal cells are actually restricted to the mammary duct, to the lactate, to the
milk duct and they have not extended beyond the duct into the normal tissue. The actual
dilemma in DCIS is how to identify patients who are at low risk, so following lumpectomy
have a very low risk of recurrence, either DCIS or invasive carcinoma, in those patients
that are less common but have a much higher risk of recurrence locally, either of DCIS
or of invasive carcinoma. The DCIS score is an assay that uses your tumor tissue that
are obtained at the time of surgery. The test measures the activity of genes in your tumor
and it identifies your level of risk, of low score correlates with a low risk of recurrence,
either DCIS or invasive. Alternatively, if the activity of the genes is high, this will
result in high DCIS score and a high DCIS score is associated with a greater likelihood
of your tumor coming back, either it is DCIS or is an invasive carcinoma.